Press releases

Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide

Controlled-release treatments can maximise efficiency and improve patient-adherence

Saint Prex, Switzerland – 10 April, 2017 – Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology Platform for the development of an injectable, controlled-release formulation of a peptide therapeutic.

Under the terms of the agreement, Alrise will conduct feasibility and scale-up studies with Ferring. Upon completion of the development work, Ferring will have the right to exercise its option and enter into a definitive agreement with Alrise to further develop and manufacture the formulation. 

“Ferring aims to harness innovative technology platforms, such as Alrise’s microparticle-technology platform, in order to provide new, controlled-release formulations of peptides and proteins for our patients,” said Alan S. Harris, Senior Vice President, R&D Executive Office, Ferring Pharmaceuticals. “Controlled, long-duration release treatments can maximise efficiency, help improve compliance to treatment, and make life simpler for our patients.”

“Alrise is committed to delivering solutions that enhance the performance of drug products in development,” said Volker Rindler, Head of Business Development and Co-Founder, Alrise Biosystems. “Together with Ferring we aim to develop a new depot formulation that, once injected, releases the drug in a controlled way and thereby ensures an effective drug level over several months.”

Ferring recently announced a number of agreements aimed at developing new formulations of peptide-based therapeutics through novel technology platforms, including a long-term collaboration with Aché Laboratórios Farmacêuticos, aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology.

ENDS

About ImSus® Technology Platform
ImSus® is a unique drug delivery technology platform for the design and manufacture of drug-loaded polymeric nano- and microparticle formulations. The patented process allows an efficient encapsulation of small molecule, peptide and protein drugs for injectable controlled release applications. Key advantages of the ImSus® technology include the exclusive use of non-harmful (non-carcinogenic) organic solvents and  the control over critical performance attributes, which aim to shorten product development times and lower costs.

About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com

About ALRISE Biosystems 
Alrise was founded in 2004 by Dr. Celal Albayrak, Dr. Volker Rindler and Dr. Heiko Seemann. In collaboration with pharmaceutical companies Alrise develops injectable as well as oral formulations based on polymeric nano- and microparticles for various substance classes. Major shareholders in the Berlin-based company are the VC companies Creathor Venture and IBB Beteiligungsgesellschaft mbH as well as Dr. Giuseppe Vita, the former CEO of Schering AG. For more information visit www.alrise.de.

For more information:

Ferring Pharmaceuticals            ALRISE Biosystems GmbH
Lindsey Rodger                          Dr. Volker Rindler
Tel. +41 58 451 40 23                Tel. +49 30 94 89 24 85
lindsey.rodger@ferring.com        rindler@alrise.de

 

 

See more Press releases

Headquarters

FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND

TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10

CONTACT

Global Locator